Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by MinichMacGregor Wealth Management LLC

MinichMacGregor Wealth Management LLC lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 16.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,400 shares of the medical equipment provider's stock after selling 15,978 shares during the quarter. Lantheus accounts for approximately 1.9% of MinichMacGregor Wealth Management LLC's holdings, making the stock its 20th biggest holding. MinichMacGregor Wealth Management LLC owned 0.11% of Lantheus worth $8,714,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. GAMMA Investing LLC boosted its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 208 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in Lantheus during the first quarter worth approximately $34,000. Signaturefd LLC grew its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 92 shares during the period. Nkcfo LLC acquired a new position in Lantheus in the 2nd quarter valued at $47,000. Finally, UMB Bank n.a. lifted its stake in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Ratings Changes

LNTH has been the subject of a number of recent analyst reports. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. Leerink Partners boosted their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Finally, Truist Financial cut their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $126.00.

Insider Activity at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company's stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Lantheus Trading Down 0.4 %

Shares of Lantheus stock traded down $0.49 during trading hours on Tuesday, hitting $114.96. The company's stock had a trading volume of 1,490,700 shares, compared to its average volume of 959,263. The business has a fifty day moving average of $108.41 and a 200 day moving average of $95.60. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $7.98 billion, a PE ratio of 18.85 and a beta of 0.51.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.